Novel .alpha.-halo-p-cycloalkylphenylacetic acids and their derivatives have been prepared. Compounds of this invention possess useful anti-inflammatory, analgestic and antipyretic antipyretic properties.

Polypeptides, in particular the polypeptide of formula I: and analogues thereof which possess inhibitory activity against human leukocyte elastase. The polypeptides may be obtained by expression using plasmidic expression systems in hosts such as E. Coli and yeast, the polypeptide of formula I being also obtainable from psoriatic plaques.

Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABA.sub.B receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy. ##STR1##

Compounds of formula (I) ##STR00001## are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.

Ligand compounds useful as extractants of certain metals from solutions. Effective also as promoters of the growth of microorganisms. A process for the preparation of such hexadentate ligands and methods of selective extraction of transition and related metal ions from admixtures with other metals.

5-Arylidene-4-oxo-2-thioxo-3-thiazolidinecarboxylic acids of formula I ##STR1## in which the symbols R.sup.1, R.sup.2, A, A.sup.1 and A.sup.2 have the significance given in the description as medicaments for the treatment of cancer diseases.

Aromatic dehydroamino acids are disclosed that are active as LFA-1 arnagonists This activity enables these compounds to prevent inflammation which is a consequence of T cell activation and accordingly reduce or eliminate inflammatory skin disease psoriasis.

Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABA.sub.B receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy ##STR1##

The invention relates to novel derivatives of quinolonecarboxylic acid and naphthyridonecarboxylic acid which are linked to a .beta.-lactam antibiotic, to their salts, to processes for their preparation and to antibacterial agents containing these derivatives.

The invention relates to new acylamino acids obtained by acylation of hydrolysates of proteins containing, essentially, fibroin and sericin as, for instance, silk. The invention provides also various compositions containing the said acylamino acids, for use in the cosmetic, hygienic, therapeutic and agricultural fields.